PA

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Parise CA et al. – The authors recommend reporting breast cancer as an ER/PR/HER2 subtype and precisely documenting demographic and tumor characteristics.

Exclusive Author Commentary
Carol A. Parise, 11/03/09

The ER/PR/HER2 subtypes in conjunction with appropriate immunhistochemical testing is a good surrogate for the molecular classification of breast cancer. This "poor man's" substitute for the molecular classification may also save healthcare dollars, an important consideration in today's economy.

   

Today in Obstetrics/Gynecology...keeping you current

Translational Research and Reproductive Senescence
The Female Patient, 12/09/09

Contraceptive Concerns: Return to Fertility
The Female Patient, 12/09/09

Nutrition in Pregnancy
The Female Patient, 12/09/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address